Abstract

Myasthenia gravis (MG) is an autoimmune disease associated with antibodies directed to the postsynaptic nicotinic acetylcholine receptor(AChR).Its essential pathogenesis is the failure of self tolerance,which results in abnormal cellular and humoral immune response to self AChR.The production of the AChR antibodies (AChR-Abs) is T cell dependent.Therefore the specific T cell is the potential target for MG specific therapy.As the progress of immunology,immune tolerance therapy for MG might specifically and effectively prevent or block the occurrence and development of MG. Key words: Myasthenia gravis; Acetyleholine receptor; Immune tolerance

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call